Biospective specializes in pre-clinical and clinical assessments of novel CNS disease and anti-cancer therapeutics using a broad range of biomarkers

WHY BIOMARKERS & IMAGING?
Biomarkers and imaging are essential elements of the FDA’s Critical Path Initiative. For more details, click HERE

Biospective and Perceptive Informatics will present a poster at ICAD 2011 on Sunday July 17 (12:30 - 3 p.m.)

July 16-21, 2011
Paris, France

  PRE-CLINICAL STUDIES
• CNS & oncology models
• In vivo MRI & PET imaging
• Autoradiography
• Histopathology
• Immunohistochemistry
• Quantitative digital pathology

  CLINICAL TRIALS
• MRI imaging studies
• PET imaging studies
• Pathology studies
• State-of-the-art image analysis

BIOSPECTIVE SERVICES
Download printer friendly description of Biospective's services HERE

Alzheimer's Association ICAD 2011

July 16-21, 2011
Paris, France
Visit us at Booth #35

Biospective's unique range of services provides a seamless translation from pre-clinical studies to early-phase clinical trials